Biotechnology Market To Reach $4.5 Trillion by 2035

Biotechnology market is projected to grow significantly from $1.5 trillion in 2025 to approximately $4.5 trillion by 2035, registering a robust CAGR of 11.5% during the forecast period (2026–2035). The market expansion is primarily driven by the rapid advancement in biologics, gene therapies, and increasing healthcare demand worldwide.

Browse the full report description of “Biotechnology Market Size, Share & Trends Analysis Report, By Product Type (Biopharmaceuticals, Biosimilars, Vaccines, Cell & Gene Therapy Products, Industrial Biotech Products, Research & Diagnostic Reagents), By Technology Type (Recombinant DNA Technology, Monoclonal Antibody Technology, Cell Therapy Technology, Gene Editing Technology, Fermentation Technology, Tissue Engineering), By End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Contract Research Organizations, Diagnostic Laboratories), Forecast Period (2026–2035)” at https://www.omrglobal.com/industry-reports/biotechnology-market

A major macro driver accelerating this growth is the rising global disease burden and aging population. According to the World Health Organization, chronic diseases account for 74% of global deaths, with cardiovascular diseases alone causing nearly 17.9 million deaths annually. This increasing prevalence of chronic and infectious diseases is pushing demand for advanced biologics, vaccines, and personalized therapies, core components of the biotechnology market.

Additionally, regulatory approvals and R&D intensity are strengthening market growth. The U.S. Food and Drug Administration reported a steady rise in biologics and gene therapy approvals, with over 20+ cell and gene therapy products approved globally by 2025, reflecting accelerated innovation. Furthermore, biologics contribute to over 55% of total pharmaceutical sales, reinforcing biotechnology’s dominance in healthcare revenue streams.

From an application standpoint, hospitals and clinics remain the dominant end users due to increasing biologics adoption in oncology and immunology treatments. According to the International Federation of Pharmaceutical Manufacturers & Associations, global pharmaceutical R&D spending exceeded $200 billion annually, with a significant share allocated to biotechnology-based drug development.

High-Growth Segment: Cell & Gene Therapy Products

Among product types, Cell & Gene Therapy Products represent the fastest-growing segment, driven by breakthroughs in CRISPR gene editing and personalized medicine. The World Intellectual Property Organization highlights a sharp increase in gene-editing patent filings, growing at over 20% annually, indicating strong innovation momentum.

Recent Developments

• In July 2025, Roche received an FDA Complete Response Letter for Columvi in DLBCL treatment. In the STARGLO Phase III trial, results showed survival benefits but were insufficient for second-line U.S. approval. In response, Roche is continuing discussions with the U.S. Food and Drug Administration and advancing further clinical studies.
• In November 2025, Moderna announced a $140 million investment to complete its U.S. mRNA manufacturing network. In the expansion, the company will add final-stage production capabilities to its Massachusetts facility. In response, this strengthens domestic production and supports large-scale manufacturing of mRNA-based therapies.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Type
  • By Technology
  • By End Users
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape – Roche Holding AG, Pfizer Inc, Johnson and Johnson, AbbVie Inc, Merck and Co, Inc, among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Biotechnology Market Report Segment

By Product Type

• Biopharmaceuticals
• Biosimilars
• Vaccines
• Cell & Gene Therapy Products
• Industrial Biotech Products (enzymes, biofuels)
• Research & Diagnostic Reagents

By Technology Type

• Recombinant DNA Technology
• Monoclonal Antibody Technology
• Cell Therapy Technology
• Gene Editing Technology (CRISPR, TALEN, ZFN)
• Fermentation Technology
• Tissue Engineering

By End User

• Hospitals & Clinics
• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Contract Research Organizations (CROs)
• Diagnostic Laboratories

Global Biotechnology Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/biotechnology-market